1. 188 Real-world data on the use of certolizumab pegol for the treatment of axial spondyloarthritis in clinical practice in Europe: 24-week interim results from a prospective non-interventional cohort study. (25th April 2018) Authors: Goodson, Nicola; Witte, Torsten; De Clerck, Luc; Galeazzi, Mauro; Collantes-Estévez, Eduardo; Kumke, Thomas; Baraliakos, Xenofon Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Certolizumab Pegol Efficacy in Patients With Non‐Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C‐Reactive Protein Status: An Analysis From the C‐axSpAnd Study. Issue 9 (22nd June 2022) Authors: Robinson, Philip C.; Maksymowych, Walter P.; Gensler, Lianne S.; Hall, Stephen; Rudwaleit, Martin; Hoepken, Bengt; Bauer, Lars; Kumke, Thomas; Kim, Mindy; de Peyrecave, Natasha; Deodhar, Atul Journal: ACR open rheumatology Issue: Volume 4:Issue 9(2022) Page Start: 794 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study. (15th November 2021) Authors: Baraliakos, Xenofon; Kruse, Sebastian; Auteri, Simone E; de Peyrecave, Natasha; Nurminen, Tommi ; Kumke, Thomas; Hoepken, Bengt; Braun, Jürgen Journal: Rheumatology Issue: Volume 61:Number 7(2022) Page Start: 2875 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0385 LONG-TERM CERTOLIZUMAB PEGOL TREATMENT OF AXIAL SPONDYLOARTHRITIS IS ASSOCIATED WITH RAPID AND SUSTAINED REDUCTION OF ACTIVE INFLAMMATION AND MINIMAL STRUCTURAL CHANGES IN THE SPINE: 4-YEAR MRI RESULTS FROM RAPID-AXSPA. (June 2019) Authors: Baraliakos, Xenofon; Kruse, Sebastian; Auteri, Simone; Peyrecave, Natasha de; Nurminen, Tommi; Kumke, Thomas; Hoepken, Bengt; Braun, Juergen Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 876 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0408 EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL OUTCOMES. (June 2019) Authors: Rudwaleit, Martin; Gensler, Lianne S.; Deodhar, Atul; Kay, Jonathan; Maksymowych, Walter P.; Haroon, Nigil; Landewé, Robert B.M.; Auteri, Simone; Peyrecave, Natasha de; Kumke, Thomas; Heijde, Désirée van der Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 891 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study. Issue 5 (3rd September 2019) Authors: Westhovens, Rene; Ravelingien, Isabelle; Vandevyvere, Klaas; Pansar, Ingrid; Purcaru, Oana; Kumke, Thomas; Gyselbrecht, Lieve Journal: Acta clinica belgica Issue: Volume 74:Issue 5(2019) Page Start: 342 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin. Issue 7 (24th April 2013) Authors: Stockis, Armel; van Lier, Jan Jaap; Cawello, Willi; Kumke, Thomas; Eckhardt, Klaus Journal: Epilepsia Issue: Volume 54:Issue 7(2013:Jul.) Page Start: 1161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. Issue 1 (16th March 2022) Authors: van der Heijde, Désirée; Gensler, Lianne S; Maksymowych, Walter P; Landewé, Robert; Rudwaleit, Martin; Bauer, Lars; Kumke, Thomas; Kim, Mindy; Auteri, Simone Emanuele; Hoepken, Bengt; Deodhar, Atul Journal: RMD open Issue: Volume 8:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OP0108 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY. (June 2019) Authors: Ritchlin, Christopher T.; Kavanaugh, Arthur; Merola, Joseph F.; Schett, Georg; Scher, Jose U.; Warren, Richard B.; Assudani, Deepak; Kumke, Thomas; Ink, Barbara; Mcinnes, Iain Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P242 CZP improves work and household productivity and social participation over 1 year of treatment in patients with non-radiographic axSpA. (20th April 2020) Authors: Gaffney, Karl; Deodhar, Atul; Gensler, Lianne; Kay, Jonathan; Maksymowych, Walter; Haroon, Nigil; Landewé, Robert; Rudwaleit, Martin; Hall, Stephen; Bauer, Lars; Hoepken, Bengt; de Peyrecave, Natasha; Kumke, Thomas; van der Heijde, Désirée Journal: Rheumatology Issue: Volume 59(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗